Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART

Journal of Clinical Virology

Volumn 33, Issue 3, 2005, Pages 206-216

  Chew, Choo Beng ^a,b   Potter, Simon J ^b   Wang, Bin ^b   Wang, Yuan Min ^b   Shaw, Chanh Op ^a   Dwyer, Dominic E ^a,b   Saksena, Nitin K ^b  

^a WESTMEAD HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

HAART; HIV 1 drug resistance; NNRTI; NRTI; PI

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CELL COMPARTMENTALIZATION; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG DOSE REGIMEN; GENETIC VARIABILITY; HEREDITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA; PREDICTION; PRIORITY JOURNAL; RELIABILITY; TREATMENT FAILURE; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS; MUTATION; PROVIRUSES; RNA, VIRAL; VIRAL LOAD;

EID: 19344370916     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2004.11.006     Document Type: Article

References (47)

1. D. Arion, N. Kaushik, S. McCormick, G. Borkow, and M.A. Parniak Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′- deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase Biochemistry 37 1998 15908 15917
2. E.J. Arts, M.E. Quinones-Mateu, J.L. Albright, J.P. Marois, C. Hough, and Z. Gu 3′-azido-3′-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants J Virol 72 1998 4858 4865
3. J.D. Baxter, D.L. Mayers, D.N. Wentworth, J.D. Neaton, M.L. Hoover, M.A. Winters CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy AIDS 14 2000 F83 F93
4. A.M. Borman, S. Paulous, and F. Clavel Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug J Gen Virol 77 1996 419 426
5. A.M. Caliendo, A. Savara, D. An, K. DeVore, J.C. Kaplan, and R.T. D'Aquila Effects of zidovudine- selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication J Virol 7 1996 2146 2153
6. Chew CB. 2003. Ph.D. Thesis. The University of Sydney, Sydney, NSW.
7. C.B. Chew, M.J. Leroi, C. Workman, and D.E. Dwyer Changes in HIV-1 viral load trends with highly active antiretroviral therapy Med J Aust 174 4 2001 199 200
8. T.W. Chun, L. Carruth, D. Finzi, X. Shen, J.A. DiGiuseppe, and H. Taylor Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection Nature 387 1997 183 188
9. T.W. Chun, D. Engel, M.M. Berrey, T. Shea, L. Corey, and A.S. Fauci Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection Proc Natl Acad Sci USA 95 15 1998 8869 8873
10. T.W. Chun, and A.S. Fauci Latent reservoirs of HIV: obstacles to the eradication of virus Proc Natl Acad Sci USA 96 1999 10958 10961
11. T.W. Chun, L. Stuyver, S.B. Mizell, L.A. Ehler, J.A. Mican, and M. Baseler Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy Proc Natl Acad Sci USA 94 1997 13193 13197
12. G. Croteau, L. Doyon, D. Thibeault, G. McKercher, L. Pilote, and D. Lamarre Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors J Virol 71 1997 1089 1096
13. S.G. Deeks, F.M. Hecht, M. Swanson, ElbeikT, R. Loftus, and P.T. Cohen HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy AIDS 13 6 1999 F35 F43
14. J.J. de Jong, J. Goudsmit, V.V. Lukashov, M.E. Hillebrand, E. Baan, and R. Huismans Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs AIDS 13 1999 75 80
15. H.L. Devereux, A. Burke, C.A. Lee, and M.A. Johnson In vivo HIV-1 compartmentalisation: drug resistance-associated mutation distribution J Med Virol 66 2002 8 12
16. J.J. Eron, S.L. Benoit, J. Jemsek, R.D. MacArthur, J. Santana, and J.B. Quinn Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200-500 CD4+ cells per cubic millimetre. North American HIV Working Party N Engl J Med 333 1995 1662 1669
17. D. Finzi, M. Hermankova, T. Pierson, L.M. Carruth, C. Buck, and R.E. Chaisson Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy Science 278 1997 1295 1300
18. M.R. Furtado, D.S. Callaway, J.P. Phair, K.J. Kunstman, J.L. Stanton, and C.A. Macken Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy N Engl J Med 340 1999 1614 1622
19. H.F. Gunthard, S.D. Frost, A.J. Leigh-Brown, C.C. Ignacio, K. Kee, and A.S. Perelson Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy J Virol 73 1999 9404 9412
20. J. Goudsmit, A. de Ronde, E. de Rooij, and R. de Boer Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215 J Virol 71 1997 4479 4484
21. A.J. Hance, V. Lemiale, J. Izopet, D. Lecossier, V. Joly, and P. Massip Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy J Virol 75 2001 6410 6417
22. P.R. Harrigan, I. Kinghorn, S. Bloor, S.D. Kemp, I. Najera, and A. Kohli Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility J Virol 70 1996 5930 5934
23. K. Hertogs, M.P. de Bethune, V. Miller, T. Ivens, P. Schel, and A. Van Cauwenberge A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs Antimicrob Agents Chemother 42 1998 269 276
24. D.J. Hooker, G. Tachedjian, A.E. Solomon, A.D. Gurusinghe, S. Land, and C. Birch An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine J Virol 70 1996 8010 8018
25. A.K. Iversen, R.W. Shafer, K. Wehrly, M.A. Winters, J.I. Mullins, and B. Chesebro Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy J Virol 70 1996 1086 1090
26. P. Kellam, C.A. Boucher, and B.A. Larder Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine Proc Natl Acad Sci USA 89 1992 1934 1938
27. N. Koch, N. Yahi, F. Ariasi, J. Fantini, and C. Tamalet Comparison of human immunodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients receiving combination drug therapy J Clin Microbiol 37 1999 1595 1597
28. B.A. Larder, and S.D. Kemp Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT) Science 246 1989 1155 1158
29. B.A. Larder, S.D. Kemp, and P.R. Harrigan Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy Science 269 1995 696 699
30. G.M. Lucas, R.E. Chaisson, and R.D. Moore Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions Ann Int Med 131 2 1999 81 87
31. J. Martinez-Picado, A.V. Savara, L. Sutton, and R.T. D'Aquila Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1 J Virol 73 1999 3744 3752
32. A. Mocroft, S. Vella, T.L. Benfield, A. Chiesi, V. Miller, and P. Gargalianos Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group Lancet 352 1998 1725 1730
33. National Centre in HIV Epidemiology and Clinical Research (Australia)/National Health and Medical Research Council (Australia). Australian HIV Surveillance Report, vol. 17, no. 3; 2001: p. 1-3.
34. F.J. Palella Jr., K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, and G.A. Satten Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 338 1998 853 860
35. S. Palmer, R.W. Shafer, and T.C. Merigan Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development AIDS 13 1999 661 667
36. D.L. Paterson, S. Swindells, J. Mohr, M. Brester, E.N. Vergis, and C. Squier Adherence to protease inhibitor therapy and outcomes in patients with HIV infection Ann Int Med 133 2000 21 30
37. C.F. Perno, A. Cozzi-Lepri, C. Balotta, F. Forbici, M. Violin, A. Bertoli Italian Cohort Naive Antiretroviral (I.CO.N.A.) Study Group Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy J Infect Dis 184 2001 983 991
38. S.J. Potter, D.E. Dwyer, and N.K. Saksena Differential distribution of HIV-1 drug resistance in vivo: evidence for infection of CD8+T cells during HAART Virology 305 2003 339 352
39. S.J. Potter, P. Lemey, G. Achaz, C.B. Chew, A.M. Vandamme, and D.E. Dwyer HIV-1 compartmentalization in diverse leukocyte populations during antiretroviral therapy J Leukoc Biol 76 2004 562 570
40. M.S. Saag, and J.M. Kilby HIV-1 and HAART: a time to cure, a time to kill Nat Med 5 1999 609 611
41. L. Sarmati, E. Nicastri, I. Uccella, G. D'Ettorre, S.G. Parisi, and L. Palmisano Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing J Clin Microbiol 41 2003 1760 1762
42. K. Van Vaerenbergh, K. Van Laethem, J. Albert, C.A. Boucher, B. Clotet, and M. Floridia Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues Antimicrob Agents Chemother 44 2000 2109 2117
43. E. Vittinghoff, S. Scheer, P. O'Malley, G. Colfax, S.D. Holmberg, and S.P. Buchbinder Combination antiretroviral therapy and recent declines in AIDS incidence and mortality J Infect Dis 179 1999 717 720
44. M.A. Wainberg, M.D. Miller, Y. Quan, H. Salomon, A.S. Mulato, and P.D. Lamy In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA Antivir Ther 4 1999 87 94
45. Y.M. Wang, W.B. Dyer, C. Workman, B. Wang, J.S. Sullivan, and N.K. Saksena Molecular evidence for drug-induced compartmentalization of HIV-1 quasi-species in a patient with periodic changes to HAART AIDS 14 2000 2265 2272
46. J.K. Wong, M. Hezareh, H.F. Gunthard, D.V. Havlir, C.C. Ignacio, and C.A. Spina Recovery of replication-competent HIV despite prolonged suppression of plasma viremia Science 278 1997 1291 1295
47. M.A. Winters, and T.C. Merigan Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nucleoside analogs Antimicrob Agents Chemother 45 2001 2276 2279